Actively Enrolling Wet AMD Clinical Trials
Wet Macular Degeneration
Wet age-related macular degeneration (Wet AMD) is characterized by the development of irregular blood vessels beneath the macula. Left untreated, these vessels can permanently damage the delicate retinal tissue. Prior to approximately 2005, effective treatment options were limited, often resulting in significant vision loss for affected patients.
However, thanks to clinical trials conducted in the early 2000s, we now have highly effective, minimally invasive, and nearly painless treatments. Unfortunately, these treatments require frequent repetition—approximately every 10 weeks—to maintain vision. This can be burdensome for both patients and caregivers.
Excitingly, we are actively collaborating in the development of the next generation of treatment options. These include longer-lasting and even more effective molecules, as well as groundbreaking gene therapy that holds the potential to essentially cure some patients.
Clinical trials offer hope during these transformative times. Below, we highlight some of the trials in which we participate and that are available to our patients. If you believe you, a friend, or a family member might be a suitable candidate, please don’t hesitate to reach out to our research team via our contact form.
ACHIEVE
AbbVie (North Chicago, IL)
ACHIEVE (M24-528) is a Phase 3b randomized, controlled, partially masked, multicenter study assessing the injection burden, adverse events, change in disease activity, and long-term preservation of visual acuity of a one-time subretinal dose of surabgene lomparvovec (ABBV-RGX-314) compared with ongoing intravitreal ranibizumab (Lucentis) in adults with previously treated neovascular AMD.
PI: Nikolas London, MD, FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: AbbVie
Contact: [email protected]
Interested in this clinical trial? Fill out our research contact form and a member of our team will contact you within 24 hours.
Amgen
Amgen (Thousand Oaks, CA)
A Phase 3, randomized, double-masked study to evaluate the efficacy, safety, and immunogenicity of ABP 938 8 mg, an investigational biosimilar to aflibercept, versus EYLEA HD (aflibercept 8 mg) in treatment-naïve participants with neovascular age-related macular degeneration.
PI: Michael Ammar, MD
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Amgen
Contact: [email protected]
Interested in this clinical trial? Fill out our research contact form and a member of our team will contact you within 24 hours.
Years in Practice in San Diego
We've been leading the way in retinal care and clinical research since 1979.